Proteasome inhibitors

(e.g., bortezomib, carfilzomib, ixazomib)

Cardio-oncological evaluation* AND BNP or NT-proBNP**

before cancer treatment begins

Cardio-oncological evaluation* AND home blood pressure monitoring, BNP or NT-proBNP**

every 3 months for 1 year, then every 6 months during all proteasome inhibitors therapy

* A cardio-oncological evaluation will systematically include at least one visit with blood pressure, blood glucose, lipid profile, GFR calculation, ECG and trans-thoracic echocardiography (TTE). Measurements of global longitudinal strain and 3D LVEF (if feasible) are recommended with the same machine.

** TTE and BNP/NT-proBNP must not be performed the day of proteasome inhibitor infusion

Logo gmedico.fr final.png

Centre Méditerranéen Hospitalo-Universitaire de Cardio-Oncologie

​Hôpital Nord, chemin des Bourrely, 13015 Marseille, France

Aix-Marseille Université

Nous contacter

  • Facebook Social Icône

Partagez: 

© 2020 by Franck Thuny